DK3581650T3 - Faktor ix polypeptidmutant, anvendelse deraf og en fremgangsmåde til fremstilling deraf - Google Patents

Faktor ix polypeptidmutant, anvendelse deraf og en fremgangsmåde til fremstilling deraf Download PDF

Info

Publication number: DK3581650T3
Authority: DK; Denmark
Prior art keywords: factor; procedure; manufacture; polypeptide mutant; mutant
Prior art date: 2008-09-15

Application number

DK19174517.3T

Other languages

English (en)

Inventor

Paolo Simioni

Original Assignee

Uniqure Biopharma B V

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-09-15

Filing date

2009-09-15

Publication date

2023-03-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41397565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3581650(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-09-15 Priority claimed from ITBO2008A000564A external-priority patent/IT1394177B1/it

2009-05-06 Priority claimed from ITBO2009A000275A external-priority patent/IT1395980B1/it

2009-09-15 Application filed by Uniqure Biopharma B V filed Critical Uniqure Biopharma B V

2023-03-13 Application granted granted Critical

2023-03-13 Publication of DK3581650T3 publication Critical patent/DK3581650T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Medicinal Chemistry (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Hematology (AREA)
Diabetes (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

DK19174517.3T 2008-09-15 2009-09-15 Faktor ix polypeptidmutant, anvendelse deraf og en fremgangsmåde til fremstilling deraf DK3581650T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
ITBO2008A000564A IT1394177B1 (it)	2008-09-15	2008-09-15	Polipeptide fattore ix modificato, sue utilizzazioni e metodo per la sua produzione
ITBO2009A000275A IT1395980B1 (it)	2009-05-06	2009-05-06	Polipeptide fattore ix modificato, sue utilizzazioni e metodo per la sua produzione
EP17175191.0A EP3252157A1 (en)	2008-09-15	2009-09-15	Factor ix polypeptide mutant, its uses and a method for its production

Publications (1)

Publication Number	Publication Date
DK3581650T3 true DK3581650T3 (da)	2023-03-13

Family

ID=41397565

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK19174517.3T DK3581650T3 (da)	2008-09-15	2009-09-15	Faktor ix polypeptidmutant, anvendelse deraf og en fremgangsmåde til fremstilling deraf
DK09748260.8T DK2337849T3 (da)	2008-09-15	2009-09-15	Faktor ix-polypeptidmutant, anvendelser deraf og fremgangsmåde til fremstiling deraf

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK09748260.8T DK2337849T3 (da)	2008-09-15	2009-09-15	Faktor ix-polypeptidmutant, anvendelser deraf og fremgangsmåde til fremstiling deraf

Country Status (19)

Country	Link
US (13)	US9249405B2 (da)
EP (5)	EP3581650B1 (da)
CA (1)	CA2737094C (da)
CY (2)	CY1125885T1 (da)
DK (2)	DK3581650T3 (da)
ES (3)	ES2985035T3 (da)
FI (5)	FI3581650T3 (da)
FR (4)	FR23C1028I1 (da)
HK (1)	HK1244507A1 (da)
HR (2)	HRP20181442T1 (da)
HU (6)	HUE067487T2 (da)
LT (5)	LT3581650T (da)
NO (2)	NO2023029I1 (da)
PL (3)	PL2337849T3 (da)
PT (1)	PT3581650T (da)
SI (1)	SI3581650T1 (da)
SM (2)	SMT202300084T1 (da)
TR (1)	TR201813067T4 (da)
WO (1)	WO2010029178A1 (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUE067487T2 (hu)	2008-09-15	2024-10-28	Uniqure Biopharma B V	IX-es faktor polipeptid mutánsa, alkalmazásai és eljárás az elõállítására
TWI595004B (zh)	2010-11-03	2017-08-11	介控生化科技公司	經修飾之第九因子多胜肽及其用途
AU2013293573B2 (en)	2012-07-25	2016-10-27	Catalyst Biosciences, Inc.	Modified Factor X polypeptides and uses thereof
LT2956477T (lt)	2013-02-15	2021-02-10	Bioverativ Therapeutics Inc.	Optimizuotas faktoriaus viii genas
EP3160478A4 (en)	2014-06-30	2018-05-16	Bioverativ Therapeutics Inc.	Optimized factor ix gene
GB201420139D0 (en)	2014-11-12	2014-12-24	Ucl Business Plc	Factor IX gene therapy
PT3313991T (pt)	2015-06-23	2024-09-27	Childrens Hospital Philadelphia	Fator ix modificado e composições, métodos e utilizações para transferência de genes para células, órgãos e tecidos
PL3411478T3 (pl)	2016-02-01	2022-10-03	Bioverativ Therapeutics Inc.	Geny zoptymalizowanego czynnika VIII
IL263801B2 (en)	2016-07-26	2024-01-01	Biomarin Pharm Inc	Novel adeno-associated virus capsid proteins
CN106497949A (zh) *	2016-10-14	2017-03-15	上海交通大学医学院附属瑞金医院	一种高活性凝血因子ix突变体、重组蛋白与融合蛋白的制备与应用
KR102386890B1 (ko)	2017-05-22	2022-04-15	다케다 야쿠힌 고교 가부시키가이샤	B형 혈우병 유전자 요법을 위한 증가된 발현을 가지는 재조합 fix 변이체를 암호화하는 바이러스 벡터
JP7764129B2 (ja)	2017-07-10	2025-11-05	ユニキュアーアイピービー．ブイ．	ヒトにおけるａａｖ遺伝子療法のための手段及び方法
US11491212B1 (en)	2017-09-27	2022-11-08	Catalyst Biosciences, Inc.	Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
WO2019217513A2 (en)	2018-05-09	2019-11-14	Biomarin Pharmaceutical Inc.	Methods of treating phenylketonuria
EP3794112A1 (en)	2018-05-14	2021-03-24	BioMarin Pharmaceutical Inc.	Stable expression of aav vectors in juvenile subjects
TW202005978A (zh)	2018-05-14	2020-02-01	美商拜奧馬林製藥公司	新穎肝靶向腺相關病毒載體
US10842885B2 (en)	2018-08-20	2020-11-24	Ucl Business Ltd	Factor IX encoding nucleotides
SG11202101560QA (en) *	2018-08-20	2021-03-30	Ucl Business Ltd	Factor ix encoding nucleotides
GB201813528D0 (en)	2018-08-20	2018-10-03	Ucl Business Plc	Factor IX encoding nucleotides
UY38389A (es) *	2018-09-27	2020-04-30	Sigilon Therapeutics Inc	Dispositivos implantables para terapia celular y métodos relacionados
BR112021007301A2 (pt)	2018-10-18	2021-07-27	Intellia Therapeutics, Inc.	composições e métodos para expressar fator ix
CN115279896A (zh)	2019-09-30	2022-11-01	比奥维拉迪维治疗股份有限公司	慢病毒载体配制品
WO2021154414A2 (en)	2020-01-29	2021-08-05	Catalyst Biosciences, Inc.	Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides
MX2023000156A (es)	2020-06-24	2023-02-16	Bioverativ Therapeutics Inc	Metodos para la eliminacion de factor viii libre de preparaciones de vectores lentivirales modificados para expresar dicha proteina.
EP4362971A1 (en) *	2021-07-01	2024-05-08	CSL Behring Lengnau AG	Factor ix subcutaneous administration with enhanced safety
WO2025022005A1 (en) *	2023-07-26	2025-01-30	Le Quellec Sandra	Intranasal administration of factor ix polypeptides

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2625412B2 (ja)	1982-08-04	1997-07-02	ブリティッシュ・テクノロジー・グループ・リミテッド	ヒト第９因子ポリペプチドをコードするｃｄｎａ
US5171569A (en)	1985-03-15	1992-12-15	National Research Development Corporation	Factor IX preparations uncontaminated by plasma components or pox virus
US4994371A (en)	1987-08-28	1991-02-19	Davie Earl W	DNA preparation of Christmas factor and use of DNA sequences
US5583107A (en)	1990-09-04	1996-12-10	Cor Therapeutics, Inc.	Agents affecting thrombosis and hemostasis
US5223408A (en)	1991-07-11	1993-06-29	Genentech, Inc.	Method for making variant secreted proteins with altered properties
GB9408717D0 (en)	1994-05-03	1994-06-22	Biotech & Biolog Scien Res	DNA sequences
US6227618B1 (en)	1996-02-23	2001-05-08	Schukra Usa, Inc.	Cable attachment for a lumbar support
EP0917566B1 (de)	1996-06-11	2004-09-22	Roche Diagnostics GmbH	Rekombinante blutgerinnungsproteasen
US6315995B1 (en)	1996-09-27	2001-11-13	The Trustees Of Columbia University In The City Of New York	Methods for treating an ischemic disorder and improving stroke outcome
ATE455552T1 (de)	1997-02-14	2010-02-15	American Nat Red Cross	Expression des active human factor ix im brustdrüsengewebe transgener tiere
US6531298B2 (en)	1997-07-21	2003-03-11	The University Of North Carolina At Chapel Hill	Factor IX antihemophilic factor with increased clotting activity
US6200560B1 (en)	1998-10-20	2001-03-13	Avigen, Inc.	Adeno-associated virus vectors for expression of factor VIII by target cells
US6759050B1 (en)	1998-12-03	2004-07-06	Avigen, Inc.	Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
US6610906B1 (en)	1999-06-09	2003-08-26	The Regents Of The University Of Michigan	Nucleotide sequences for gene regulation and methods of use thereof
US7109170B2 (en)	1999-06-16	2006-09-19	Saint Louis University	Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
US20040102388A1 (en)	2000-03-22	2004-05-27	High Katherine A.	Modified blood clotting factors and methods of use
AU2001269961A1 (en)	2000-07-06	2002-01-21	Guilford Pharmaceuticals	Improved polymers and polymerization processes
AU2002226028A1 (en)	2000-11-14	2002-05-27	Board Of Regents, Unversity Of Texas Systems	Mutant human factor ix with an increased resistance to inhibition by heparin
US20040133930A1 (en)	2002-03-11	2004-07-08	Cooper Julian D.	Production of high levels of transgenic factor ix without gene rescue, and its therapeutic uses
WO2002096454A1 (en)	2001-05-31	2002-12-05	D. Collen Research Foundation Vzw	Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
CN1547608A (zh)	2001-09-04	2004-11-17	Ĭ��ר��޹�˾	经修饰的因子ix
US7179617B2 (en)	2001-10-10	2007-02-20	Neose Technologies, Inc.	Factor IX: remolding and glycoconjugation of Factor IX
US20040009151A1 (en)	2002-04-04	2004-01-15	Kay Mark A.	Methods for delivering recombinant adeno-associated virus virions to the liver of a mammal
US20060292117A1 (en)	2002-04-17	2006-12-28	Loiler Scott A	Improved rAAv vectors
EP2444810A3 (en)	2002-10-02	2013-01-02	Catalyst Biosciences, Inc.	Proteases mutants with altered specificity and uses thereof
PT1625210E (pt)	2003-05-21	2011-03-15	Genzyme Corp	Métodos para produzir preparações de vírions de aav recombinantes substancialmente livres de capsídeos vazios
US20060040856A1 (en)	2003-12-03	2006-02-23	Neose Technologies, Inc.	Glycopegylated factor IX
GB0329681D0 (en)	2003-12-23	2004-01-28	Delta Biotechnology Ltd	Gene expression technique
JP2008509688A (ja)	2004-08-17	2008-04-03	ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー	改変ビタミンｋ依存性ポリペプチド
EP1627771B1 (de)	2004-08-19	2008-10-15	Gerd Bär	Hubladebühne mit querverschiebbarem Verbindungsrohr
WO2006031226A1 (en)	2004-09-13	2006-03-23	Saint Louis University	Region of factor ixa protease domain that interacts with factor viiia and methods therefor
DK1804839T3 (da)	2004-09-22	2012-04-10	St Jude Childrens Res Hospital	Forbedret ekspression af faktor ix i genterapivektorer
US7998930B2 (en)	2004-11-04	2011-08-16	Hanall Biopharma Co., Ltd.	Modified growth hormones
CA2591544A1 (en)	2004-12-15	2006-06-22	The University Of North Carolina At Chapel Hill	Chimeric vectors
WO2007047995A2 (en)	2005-10-21	2007-04-26	Catalyst Biosciences, Inc.	Modified proteases that inhibit complement activation
WO2007059473A2 (en)	2005-11-12	2007-05-24	Introgen Therapeutics, Inc.	Methods for the production and purification of adenoviral vectors
EP1791039A1 (fr)	2005-11-25	2007-05-30	The Swatch Group Research and Development Ltd.	Spiral en verre athermique pour mouvement d'horlogerie et son procédé de fabrication
CA2633661C (en)	2005-12-21	2019-06-04	University Of North Carolina At Chapel Hill	Method of producing biologically active vitamin k dependent proteins by recombinant methods
US7867484B2 (en)	2006-01-27	2011-01-11	University Of North Carolina At Chapel Hill	Heparin and heparan sulfate binding chimeric vectors
US7375084B2 (en)	2006-03-07	2008-05-20	Baxter International Inc.	Highly phosphorylated and sulfated recombinant factor IX
US20080003202A1 (en)	2006-03-28	2008-01-03	Thierry Guyon	Modified interferon-beta (IFN-beta) polypeptides
EP2007795B1 (en)	2006-03-30	2016-11-16	The Board Of Trustees Of The Leland Stanford Junior University	Aav capsid proteins
EP2009990B1 (en)	2006-04-07	2016-09-21	The Board of Regents of The University of Texas System	Methods and compositions related to adenoassociated virus-phage particles
BRPI0712008A2 (pt)	2006-05-24	2012-01-10	Novo Nordisk Healthcare Ag	derivados e análogos de fix prolongados
US20070280906A1 (en)	2006-06-03	2007-12-06	Ognjen Petras	Method to generate mirrored adenoassociated viral vectors
ES2535877T3 (es)	2006-06-19	2015-05-18	Asklepios Biopharmaceutical, Inc.	Genes de Factor VIII y Factor IX modificados y vectores para la terapia génica
TW200804416A (en)	2006-06-19	2008-01-16	Nautilus Technology Llc	Modified coagulation factor IX polypeptides and use thereof for treatment
US7700734B2 (en)	2007-01-09	2010-04-20	Shu-Wha Lin	Recombinant human factor IX and use thereof
EP2108045B1 (en)	2007-02-01	2013-12-11	Baxter International Inc.	Improved fix-mutant proteins for hemophilia b treatment
WO2008119815A1 (en)	2007-04-02	2008-10-09	Novo Nordisk A/S	Subcutaneous administration of coagulation factor ix
US20100137211A1 (en)	2007-04-11	2010-06-03	Monahan Paul E	Methods and compositions for intra-articular coagulation proteins
BRPI0705943A2 (pt)	2007-04-19	2008-12-09	Nautilus Biotech	formulaÇÕes de dosagem oral de polipeptÍdeos resistentes À protease e usos das mesmas para tratamento
US20080260820A1 (en)	2007-04-19	2008-10-23	Gilles Borrelly	Oral dosage formulations of protease-resistant polypeptides
US20090030072A1 (en)	2007-07-03	2009-01-29	Sucampo Ag	Pharmaceutical combination of opioid and prostaglandin compound
CN104004739A (zh)	2007-10-15	2014-08-27	北卡罗来纳-查佩尔山大学	半衰期延长的人因子ix变体
AU2009244633A1 (en) *	2008-04-16	2009-11-12	Bayer Healthcare Llc	Modified Factor IX polypeptides and uses thereof
WO2009140015A2 (en)	2008-04-16	2009-11-19	Bayer Healthcare Llc	Site-directed modification of factor ix
EP2444491B1 (en)	2008-04-21	2016-11-16	Novo Nordisk Healthcare Ag	Hyperglycosylated human coagulation factor IX
EP2149603A1 (en)	2008-07-28	2010-02-03	DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH	Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders
HUE067487T2 (hu)	2008-09-15	2024-10-28	Uniqure Biopharma B V	IX-es faktor polipeptid mutánsa, alkalmazásai és eljárás az elõállítására
ES2524974T3 (es)	2009-06-25	2014-12-16	The University Of North Carolina At Chapel Hill	Moléculas del Factor VII quimérico
CA2769258A1 (en)	2009-07-31	2011-02-03	Bayer Healthcare Llc	Modified factor ix polypeptides and uses thereof
TWI595004B (zh)	2010-11-03	2017-08-11	介控生化科技公司	經修飾之第九因子多胜肽及其用途
US10398787B2 (en)	2012-10-26	2019-09-03	Vrije Universiteit Brussel	Vectors for liver-directed gene therapy of hemophilia and methods and use thereof
EP2881463A1 (en)	2013-12-09	2015-06-10	DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH	Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders
EP3160478A4 (en)	2014-06-30	2018-05-16	Bioverativ Therapeutics Inc.	Optimized factor ix gene
JP6879486B2 (ja)	2015-03-17	2021-06-02	フリーイェ・ユニヴェルシテイト・ブリュッセルＶｒｉｊｅＵｎｉｖｅｒｓｉｅｉｔＢｒｕｓｓｅｌ	Ｆｖｉｉｉおよびｆｉｘ用の最適化された肝臓特異的発現系
US10058624B2 (en)	2015-04-16	2018-08-28	Emory University	Recombinant promoters and vectors for protein expression in liver and use thereof
PT3313991T (pt)	2015-06-23	2024-09-27	Childrens Hospital Philadelphia	Fator ix modificado e composições, métodos e utilizações para transferência de genes para células, órgãos e tecidos
MX2018001497A (es)	2015-08-03	2018-05-15	Bioverativ Therapeutics Inc	Proteinas de fusion de factor ix y metodos para producirlas y usarlas.
AU2017248659B2 (en)	2016-04-15	2022-08-11	The Trustees Of The University Of Pennsylvania	Gene therapy for treating hemophilia A
WO2017180861A1 (en)	2016-04-15	2017-10-19	The Trustees Of The University Of Pennsulvania	Gene therapy for treating hemophilia b
JP7764129B2 (ja)	2017-07-10	2025-11-05	ユニキュアーアイピービー．ブイ．	ヒトにおけるａａｖ遺伝子療法のための手段及び方法
US20210228738A1 (en)	2017-07-17	2021-07-29	INSERM (Institut National de la Santé et de la Recherche Médicale)	Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins

2009
- 2009-09-15 HU HUE21200005A patent/HUE067487T2/hu unknown
- 2009-09-15 US US13/063,898 patent/US9249405B2/en not_active Ceased
- 2009-09-15 SI SI200932179T patent/SI3581650T1/sl unknown
- 2009-09-15 EP EP19174517.3A patent/EP3581650B1/en active Active
- 2009-09-15 DK DK19174517.3T patent/DK3581650T3/da active
- 2009-09-15 HR HRP20181442TT patent/HRP20181442T1/hr unknown
- 2009-09-15 EP EP17175191.0A patent/EP3252157A1/en not_active Ceased
- 2009-09-15 EP EP22214327.3A patent/EP4219547A3/en active Pending
- 2009-09-15 HR HRP20230259TT patent/HRP20230259T1/hr unknown
- 2009-09-15 SM SM20230084T patent/SMT202300084T1/it unknown
- 2009-09-15 PT PT191745173T patent/PT3581650T/pt unknown
- 2009-09-15 PL PL09748260T patent/PL2337849T3/pl unknown
- 2009-09-15 US US18/153,894 patent/USRE50288E1/en active Active
- 2009-09-15 HU HUE19174517A patent/HUE061345T2/hu unknown
- 2009-09-15 ES ES21200005T patent/ES2985035T3/es active Active
- 2009-09-15 PL PL21200005.3T patent/PL4032979T3/pl unknown
- 2009-09-15 FI FIEP19174517.3T patent/FI3581650T3/fi active
- 2009-09-15 DK DK09748260.8T patent/DK2337849T3/da active
- 2009-09-15 ES ES09748260.8T patent/ES2687038T3/es active Active
- 2009-09-15 EP EP09748260.8A patent/EP2337849B1/en not_active Revoked
- 2009-09-15 PL PL19174517.3T patent/PL3581650T3/pl unknown
- 2009-09-15 CA CA2737094A patent/CA2737094C/en active Active
- 2009-09-15 EP EP21200005.3A patent/EP4032979B1/en active Active
- 2009-09-15 ES ES19174517T patent/ES2940323T3/es active Active
- 2009-09-15 TR TR2018/13067T patent/TR201813067T4/tr unknown
- 2009-09-15 SM SM20180468T patent/SMT201800468T1/it unknown
- 2009-09-15 WO PCT/EP2009/061935 patent/WO2010029178A1/en not_active Ceased
- 2009-09-15 LT LTEP19174517.3T patent/LT3581650T/lt unknown
2015
- 2015-12-29 US US14/981,981 patent/US20160122740A1/en not_active Abandoned
2017
- 2017-07-14 US US15/650,070 patent/US9982248B2/en active Active
2018
- 2018-03-21 HK HK18103924.5A patent/HK1244507A1/en unknown
- 2018-05-25 US US15/989,665 patent/US10465180B2/en active Active
2019
- 2019-10-01 US US16/589,851 patent/US20200231958A1/en not_active Abandoned
- 2019-12-09 US US16/707,414 patent/US20200190498A1/en not_active Abandoned
2020
- 2020-02-11 US US16/787,456 patent/US20200199564A1/en not_active Abandoned
2021
- 2021-03-26 US US17/213,897 patent/US20210214704A1/en active Pending
- 2021-03-26 US US17/213,848 patent/US20210238573A1/en not_active Abandoned
- 2021-09-10 US US17/447,372 patent/US20220002702A1/en not_active Abandoned
- 2021-12-08 US US17/643,326 patent/US20220090042A1/en not_active Abandoned
2023
- 2023-03-14 CY CY20231100138T patent/CY1125885T1/el unknown
- 2023-07-25 FI FIC20230026C patent/FIC20230026I1/fi unknown
- 2023-07-25 HU HUS2300024C patent/HUS2300024I1/hu unknown
- 2023-07-26 FR FR23C1028C patent/FR23C1028I1/fr active Active
- 2023-07-27 LT LTPA2023521C patent/LTPA2023521I1/lt unknown
- 2023-07-27 CY CY2023016C patent/CY2023016I2/el unknown
- 2023-07-31 NO NO2023029C patent/NO2023029I1/no unknown
2024
- 2024-10-29 LT LTPA2024529C patent/LTPA2024529I1/lt unknown
- 2024-10-29 LT LTPA2024530C patent/LTPA2024530I1/lt unknown
- 2024-10-29 FI FIC20240036C patent/FIC20240036I1/fi unknown
- 2024-10-29 FI FIC20240037C patent/FIC20240037I1/fi unknown
- 2024-10-30 HU HUS2400036C patent/HUS2400036I1/hu unknown
- 2024-10-30 FR FR24C1040C patent/FR24C1040I1/fr active Active
- 2024-10-30 HU HUS2400037C patent/HUS2400037I1/hu unknown
- 2024-10-30 FR FR24C1041C patent/FR24C1041I1/fr active Active
2025
- 2025-01-16 US US19/024,178 patent/US20250179462A1/en not_active Abandoned
- 2025-01-21 NO NO2025007C patent/NO2025007I1/no unknown
- 2025-01-21 FR FR25C1004C patent/FR25C1004I1/fr active Active
- 2025-01-22 FI FIC20250007C patent/FIC20250007I1/fi unknown
- 2025-01-23 LT LTPA2025503C patent/LTPA2025503I1/lt unknown
- 2025-01-23 HU HUS2500006C patent/HUS2500006I1/hu unknown

Also Published As

Publication number	Publication date
HUE061345T2 (hu)	2023-06-28
FI3581650T3 (fi)	2023-03-23
HUS2400036I1 (hu)	2024-11-28
US20220002702A1 (en)	2022-01-06
TR201813067T4 (tr)	2018-09-21
EP3581650B1 (en)	2022-12-28
FR23C1028I1 (fr)	2023-10-06
HUS2500006I1 (hu)	2025-02-28
HK1244507A1 (en)	2018-08-10
US20220090042A1 (en)	2022-03-24
EP3581650A2 (en)	2019-12-18
ES2985035T3 (es)	2024-11-04
PT3581650T (pt)	2023-03-08
HUS2400037I1 (hu)	2024-11-28
PL2337849T3 (pl)	2018-11-30
FR24C1040I1 (fr)	2024-12-06
LTPA2024530I1 (da)	2024-11-25
SMT202300084T1 (it)	2023-05-12
LTPA2025503I1 (da)	2025-02-10
EP4219547A3 (en)	2023-10-18
EP4032979B1 (en)	2024-05-01
US20200231958A1 (en)	2020-07-23
US20210214704A1 (en)	2021-07-15
HUE067487T2 (hu)	2024-10-28
EP3581650A3 (en)	2020-03-25
FR24C1041I1 (fr)	2024-12-06
US20180258413A1 (en)	2018-09-13
HRP20181442T1 (hr)	2018-12-14
CY2023016I1 (el)	2024-02-16
CA2737094C (en)	2018-02-20
CA2737094A1 (en)	2010-03-18
EP3252157A1 (en)	2017-12-06
EP2337849A1 (en)	2011-06-29
SI3581650T1 (sl)	2023-06-30
EP2337849B1 (en)	2018-06-13
EP4219547A2 (en)	2023-08-02
US10465180B2 (en)	2019-11-05
HRP20230259T1 (hr)	2023-04-28
PL3581650T3 (pl)	2023-05-22
ES2687038T3 (es)	2018-10-23
EP4032979C0 (en)	2024-05-01
CY1125885T1 (el)	2024-02-16
EP4032979A1 (en)	2022-07-27
CY2023016I2 (el)	2024-02-16
US20110244550A1 (en)	2011-10-06
NO2023029I1 (no)	2023-07-31
FIC20230026I1 (fi)	2023-07-25
FIC20250007I1 (fi)	2025-01-22
US9982248B2 (en)	2018-05-29
US20200199564A1 (en)	2020-06-25
US9249405B2 (en)	2016-02-02
HUS2300024I1 (hu)	2023-08-28
US20200190498A1 (en)	2020-06-18
LT3581650T (lt)	2023-05-10
PL4032979T3 (pl)	2024-09-30
LTPA2023521I1 (da)	2023-08-25
SMT201800468T1 (it)	2018-11-09
USRE50288E1 (en)	2025-02-04
CA2737094F (en)	2010-03-18
US20210238573A1 (en)	2021-08-05
DK2337849T3 (da)	2018-10-01
US20250179462A1 (en)	2025-06-05
NO2025007I1 (no)	2025-01-21
FIC20240036I1 (fi)	2024-10-29
LTPA2024529I1 (da)	2024-12-10
FIC20240037I1 (fi)	2024-10-30
US20160122740A1 (en)	2016-05-05
US20170355973A1 (en)	2017-12-14
WO2010029178A1 (en)	2010-03-18
FR25C1004I1 (fr)	2025-02-28
ES2940323T3 (es)	2023-05-05

Publication	Publication Date	Title
DK3581650T3 (da)	2023-03-13	Faktor ix polypeptidmutant, anvendelse deraf og en fremgangsmåde til fremstilling deraf
DK2687596T3 (da)	2016-02-29	Faktor VII-polypeptider som er modificerede og anvendelser deraf
DK2270818T3 (da)	2020-06-15	Polyelektrolyt og fremgangsmåde til fremstilling af polyelektrolytten
NO2017033I2 (no)	2017-07-11	baricitinib og farmasøytisk akseptable salter derav
DK2120591T3 (da)	2013-01-14	Ny drikkeyoghurt og fremgangsmåde til fremstilling deraf
DK3614595T3 (da)	2022-08-01	Fremgangsmåde og indretning til forbedrede statusrapporter
DK2635677T3 (da)	2020-04-06	Modificeret faktor IX-polypeptider og anvendelser deraf
IL208718A0 (en)	2010-12-30	Modified factor ix polypeptides and uses thereof
DK2147315T3 (da)	2013-09-23	Diabetesrelaterede biomarkører og fremgangsmåder til anvendelse deraf
EP2209374A4 (en)	2011-08-17	TUBULYSINS AND METHODS OF PREPARATION THEREOF
ZA200810738B (en)	2018-11-28	Polypeptide
BRPI0813942A2 (pt)	2014-12-30	Polipeptídio ace2
DK2235254T3 (da)	2014-08-11	Fremgangsmåde til forbehandling af et lignocellulosemateriale med henblik på at fremstille bioethanol, og bioethanolfremstillingsfremgangsmåde
DK2281164T3 (da)	2013-11-11	Fremgangsmåde til at fremstille en cementklinker, og cementklinkerproduktionsanlæg
CR10571A (es)	2009-05-14	Vacuna virica recombinante
DK2337837T3 (da)	2013-06-24	Alpha-amylase-blandinger og fremgangsmåder til anvendelse heraf
BRPI0916667A2 (pt)	2017-07-04	produção de gás natural liquefeito
IL232394A0 (en)	2014-06-30	Peptides and epitopes against p2x7
ZA201000283B (en)	2011-06-29	Reinigung pegylierter polypeptide
DK2993233T3 (da)	2019-08-19	Forbedret promoter og en fremgangsmåde til fremstilling af l-lysin ved anvendelse af samme
PL2106225T3 (pl)	2017-07-31	Pościel aromaterapeutyczna i sposób jej wytwarzania
DK2350554T3 (da)	2013-04-15	Fremgangsmåde til fremstilling af en granatsikker og skudsikker struktur, og granatsikker og skudsikker struktur
DK2347757T3 (da)	2013-03-18	Naturlig allicintablet og fremgangsmåde til fremstilling heraf
IL200019A0 (en)	2010-04-15	Polypeptide films and methods
PL2158095T3 (pl)	2017-09-29	Element płaski i sposób jego wytwarzania